Cargando…

Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era

First-line treatment of centrally involved diabetic macular oedema (CI-DMO) is often with an anti-vascular endothelial growth factor (anti-VEGF) agent. Although this can provide efficacy in the majority of eyes, a sizeable proportion do not respond sufficiently and many continue to receive anti-VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Downey, Louise, Acharya, Nachiketa, Devonport, Helen, Gale, Richard, Habib, Maged, Manjunath, Vina, Mukherjee, Rajarshi, Severn, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088120/ https://www.ncbi.nlm.nih.gov/pubmed/34192155 http://dx.doi.org/10.1136/bmjophth-2020-000696

Ejemplares similares

The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract
por: Habib, Maged S, et al.
Publicado: (2005)

Intravitreal aflibercept for treatment of macular oedema associated with immune recovery uveitis
por: Rothova, Aniki, et al.
Publicado: (2020)

Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
por: Gale, Richard, et al.
Publicado: (2021)

Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
por: Loutfi, Mohamed, et al.
Publicado: (2014)

Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
por: Wong, Yun, et al.
Publicado: (2016)

INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations
por: Yang, Yit, et al.
Publicado: (2015)

Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
por: Majumder, Parthopratim Dutta, et al.
Publicado: (2016)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia
por: Spooner, Kimberly L, et al.
Publicado: (2019)

Change in choroidal volume after dexamethasone intravitreal implant in eyes with diabetic macular oedema
por: Posch‐Pertl, Laura, et al.
Publicado: (2018)

Outcome of intravitreal Avastin® injections in patients with macular oedema in Uganda: a cohort study
por: Kabunga, Rachel R., et al.
Publicado: (2022)

Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
por: McCloskey, Clare F., et al.
Publicado: (2018)

Retinal arteriolar oxygen saturation predicts the need for intravitreal aflibercept in patients with diabetic macular oedema
por: Blindbæk, Søren Leer, et al.
Publicado: (2020)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy
por: Newcott, Eric K., et al.
Publicado: (2015)

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema
por: Abdel-Hay, Ahmed, et al.
Publicado: (2018)

12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation
por: Barteselli, Giulio, et al.
Publicado: (2014)

Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants
por: Yang, Y, et al.
Publicado: (2015)

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair
por: Alfaqawi, Fadi, et al.
Publicado: (2018)

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
por: Zirpel, Johanna J., et al.
Publicado: (2021)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study
por: Fraser-Bell, Samantha, et al.
Publicado: (2023)

Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study
por: Mitchell, Paul, et al.
Publicado: (2023)

Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
por: Amoaku, Winfried M., et al.
Publicado: (2020)

Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial
por: Lois, Noemi, et al.
Publicado: (2019)

Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema - a comparative pilot study
por: Norlaili, Mustapha, et al.
Publicado: (2011)

Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
por: Mishra, S. K., et al.
Publicado: (2018)

Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema
por: Inagaki, Keiji, et al.
Publicado: (2019)

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema
por: Podkowinski, Dominika, et al.
Publicado: (2019)

Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion
por: Pidro, Ajla, et al.
Publicado: (2022)

Healthcare expenditure of intravitreal anti‐vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema
por: Hertzberg, Silvia NW, et al.
Publicado: (2022)

Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials
por: Wei, Qingquan, et al.
Publicado: (2019)

Short‐time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age‐related macular degeneration
por: Mitsch, Christoph, et al.
Publicado: (2019)

Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
por: Talks, S. James, et al.
Publicado: (2019)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review
por: Ahn, Seong Joon, et al.
Publicado: (2018)

Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials
por: Danis, Ronald P, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cgfags8sv8esd2qbhp4k1vegra